Addressing Gaps in Care for Non-Small Cell Lung Cancer
Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, give final thoughts on unmet needs in the non-small cell lung cancer space to inform future treatment strategies.
This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.
Forde and Cascone discuss the unmet needs and future directions in the preoperative treatment of NSCLC. Despite the recent advances in this setting, there remain uncertainties regarding which patients will benefit from neoadjuvant, adjuvant, or perioperative approaches. It is unclear which patients without a pathologic complete response (pCR) should continue treatment and whether those with a pCR should continue therapy as well.
Tailoring treatment strategies based on subgroups and biomarkers is a critical unmet need. Real-time informative factors, such as PD-L1 expression, ctDNA clearance, staging, and other markers, could help determine which approach is most suitable for individual patients. The next generation of trials and preclinical and translational work should aim to address these questions.
As observed in advanced disease, the segmentation of patient populations and selection based on tumor biomarkers and other elements may allow for more personalized treatment in the early-stage setting. Rather than treating all patients with the same 1-year or 9-week treatment, tailoring therapy more specifically is a goal for the future. With the rapid progress made in recent years, there is hope for continued advancements in the field.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
